Legato Capital Management LLC Sells 1,193 Shares of Perrigo Company plc (NYSE:PRGO)

Legato Capital Management LLC reduced its holdings in Perrigo Company plc (NYSE:PRGO) by 10.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,376 shares of the company’s stock after selling 1,193 shares during the quarter. Legato Capital Management LLC’s holdings in Perrigo were worth $267,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC increased its holdings in Perrigo by 5.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,092,398 shares of the company’s stock worth $28,402,000 after purchasing an additional 52,696 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Perrigo in the fourth quarter worth approximately $149,000. Pacer Advisors Inc. increased its holdings in shares of Perrigo by 2.1% during the fourth quarter. Pacer Advisors Inc. now owns 20,337 shares of the company’s stock valued at $523,000 after acquiring an additional 427 shares in the last quarter. KBC Group NV increased its holdings in shares of Perrigo by 2,375.8% during the fourth quarter. KBC Group NV now owns 111,832 shares of the company’s stock valued at $2,875,000 after acquiring an additional 107,315 shares in the last quarter. Finally, Sound Income Strategies LLC increased its holdings in shares of Perrigo by 28.6% during the fourth quarter. Sound Income Strategies LLC now owns 482,811 shares of the company’s stock valued at $12,413,000 after acquiring an additional 107,427 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors.

Perrigo Stock Down 1.3 %

Shares of NYSE:PRGO opened at $24.48 on Friday. The stock has a market cap of $3.34 billion, a price-to-earnings ratio of -20.93 and a beta of 0.54. The company has a quick ratio of 1.77, a current ratio of 2.56 and a debt-to-equity ratio of 0.94. Perrigo Company plc has a 12-month low of $23.14 and a 12-month high of $33.46. The business’s 50 day moving average is $25.25 and its 200 day moving average is $26.38.

Insider Activity at Perrigo

In other Perrigo news, Director Jeffrey B. Kindler sold 17,598 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the transaction, the director now owns 5,409 shares of the company’s stock, valued at approximately $152,912.43. The trade was a 76.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.70% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently commented on PRGO. StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a report on Monday, February 10th. Piper Sandler downgraded Perrigo from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $34.00 to $27.00 in a report on Monday, January 6th. Finally, Argus downgraded Perrigo from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.00.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.